$1,318.00
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, a 10-year disease prevalence forecast, probability of success, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Irritable Bowel Syndrome (IBS) market, comprising key marketed and pipeline drugs, clinical trials, licensing and asset acquisition deals, recent events and analyst opinion, a 10-year disease prevalence forecast, and probability of success, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
9 TREATMENT
9 Laxatives
9 Antidiarrheal drugs
9 Antispasmodics
9 Antidepressants
9 Serotonin receptor agonists
10 Chloride channel activators
10 Guanylyl cyclase C agonists
10 Antibiotics
10 Opioid receptors
10 Probiotics
12 EPIDEMIOLOGY
17 MARKETED DRUGS
20 PIPELINE DRUGS
25 RECENT EVENTS AND ANALYST OPINION
25 ORP-101 for IBS (January 4, 2022)
26 GSK3352589 for IBS (June 3, 2021)
29 PROBABILITY OF SUCCESS
30 LICENSING AND ASSET ACQUISITION DEALS
30 France’s Mayoly Spindler Set To Acquire Ipsen’s Consumer Business
31 REVENUE OPPORTUNITY
33 CLINICAL TRIAL LANDSCAPE
34 Sponsors by status
35 Sponsors by phase
36 Recent events
38 BIBLIOGRAPHY
40 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of IBS, 2021–30
20 Figure 2: Overview of pipeline drugs for IBS in the US
20 Figure 3: Pipeline drugs for IBS, by company
21 Figure 4: Pipeline drugs for IBS, by drug type
21 Figure 5: Pipeline drugs for IBS, by classification
26 Figure 6: ORP-101 for IBS (January 4, 2022): Phase II – PREVAIL
28 Figure 7: GSK3352589 for IBS (June 3, 2021): Phase IIa – 201 (Diarrhea-predominant)
29 Figure 8: Probability of success in the gastroenterology (non inflammatory bowel disease)-other pipeline
33 Figure 9: Clinical trials in IBS
33 Figure 10: Top 10 drugs for clinical trials in IBS
34 Figure 11: Top 10 companies for clinical trials in IBS
34 Figure 12: Trial locations in IBS
35 Figure 13: IBS trials status
36 Figure 14: IBS trials sponsors, by phase
LIST OF TABLES
13 Table 1: Prevalent cases of IBS, 2021–30
15 Table 2: Prevalent cases of IBS, by gender, 2021
16 Table 3: Prevalence of IBS, by gender, 2021
18 Table 4: Marketed drugs for IBS
22 Table 5: Pipeline drugs for IBS in the US
25 Table 6: ORP-101 for IBS (January 4, 2022)
27 Table 7: GSK3352589 for IBS (June 3, 2021)
31 Table 8: Historical global sales, by drug ($m), 2017–21
32 Table 9: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!